116 related articles for article (PubMed ID: 16932026)
1. Diagnostic relevance of the immunohistochemical detection of growth factors in benign and malignant cartilaginous tumors.
Falcone G; Rossi ED; Maccauro G; de Santis V; Rosa MA; Capelli A; Fadda G
Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):334-40. PubMed ID: 16932026
[TBL] [Abstract][Full Text] [Related]
2. Expression of connective tissue growth factor in cartilaginous tumors.
Shakunaga T; Ozaki T; Ohara N; Asaumi K; Doi T; Nishida K; Kawai A; Nakanishi T; Takigawa M; Inoue H
Cancer; 2000 Oct; 89(7):1466-73. PubMed ID: 11013359
[TBL] [Abstract][Full Text] [Related]
3. Expression of MMP-9 decreases metastatic potential of Chondrosarcoma: an immunohistochemical study.
Malcherczyk D; Heyse TJ; El-Zayat BF; Kunzke V; Moll R; Fuchs-Winkelmann S; Paletta JRJ
BMC Musculoskelet Disord; 2018 Jan; 19(1):9. PubMed ID: 29316907
[TBL] [Abstract][Full Text] [Related]
4. In malignant cartilagenous tumors, immunohistochemical expression of procollagen PC1CP peptide is higher and that of PC2CP lower than in benign cartilaginous lesions.
Delaunay-Lemarie C; Vincourt JB; Marie B; Battaglia-Hsu SF; Etienne S; Sirveaux F; Nguyen Thi PL; Magdalou J; Vignaud JM; Gauchotte G
Virchows Arch; 2015 Sep; 467(3):329-37. PubMed ID: 26100916
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein expression in cartilaginous tumors.
Rosier RN; O'Keefe RJ; Teot LA; Fox EJ; Nester TA; Puzas JE; Reynolds PR; Hicks DG
J Surg Oncol; 1997 Jun; 65(2):95-105. PubMed ID: 9209520
[TBL] [Abstract][Full Text] [Related]
6. Conventional Primary Central Chondrosarcoma of the Pelvis: Prognostic Factors and Outcome of Surgical Treatment in 162 Patients.
Bus MPA; Campanacci DA; Albergo JI; Leithner A; van de Sande MAJ; Gaston CL; Caff G; Mettelsiefen J; Capanna R; Tunn PU; Jeys LM; Dijkstra PDS
J Bone Joint Surg Am; 2018 Feb; 100(4):316-325. PubMed ID: 29462035
[TBL] [Abstract][Full Text] [Related]
7. Chondrosarcoma of the phalanx: a locally aggressive lesion with minimal metastatic potential: a report of 35 cases and a review of the literature.
Bovée JV; van der Heul RO; Taminiau AH; Hogendoorn PC
Cancer; 1999 Nov; 86(9):1724-32. PubMed ID: 10547545
[TBL] [Abstract][Full Text] [Related]
8. Rb-loss is associated with high malignancy in chondrosarcoma.
Röpke M; Boltze C; Meyer B; Neumann HW; Roessner A; Schneider-Stock R
Oncol Rep; 2006 Jan; 15(1):89-95. PubMed ID: 16328039
[TBL] [Abstract][Full Text] [Related]
9. Locally recurrent chondrosarcoma of the pelvis and limbs can only be controlled by wide local excision.
Laitinen MK; Parry MC; Le Nail LR; Wigley CH; Stevenson JD; Jeys LM
Bone Joint J; 2019 Mar; 101-B(3):266-271. PubMed ID: 30813783
[TBL] [Abstract][Full Text] [Related]
10. Expression of aurora kinase A and B in chondrosarcoma and its relationship with the prognosis.
Liang X; Wang D; Wang Y; Zhou Z; Zhang J; Li J
Diagn Pathol; 2012 Jul; 7():84. PubMed ID: 22809428
[TBL] [Abstract][Full Text] [Related]
11. Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome.
Sulzbacher I; Birner P; Trieb K; Mühlbauer M; Lang S; Chott A
Am J Surg Pathol; 2001 Dec; 25(12):1520-7. PubMed ID: 11717542
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis.
Nakagawa SA; Lopes A; Lopes de Carvalho A; Rossi BM; Werneck da Cunha I; Soares FA; Chung WT; Alves LA
J Bone Joint Surg Am; 2010 Jul; 92(8):1738-46. PubMed ID: 20660237
[TBL] [Abstract][Full Text] [Related]
13. Low-grade chondrosarcoma of long bones treated with intralesional curettage followed by application of phenol, ethanol, and bone-grafting.
Verdegaal SH; Brouwers HF; van Zwet EW; Hogendoorn PC; Taminiau AH
J Bone Joint Surg Am; 2012 Jul; 94(13):1201-7. PubMed ID: 22760388
[TBL] [Abstract][Full Text] [Related]
14. The clinical pathological significance of FRAT1 and ROR2 expression in cartilage tumors.
He L; Yang Z; Zhou J; Wang W
Clin Transl Oncol; 2015 Jun; 17(6):438-45. PubMed ID: 25387569
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma.
Häckel CG; Krueger S; Grote HJ; Oshiro Y; Hodges S; Johnston DA; Johnson ME; Roessner A; Ayala AG; Czerniak B
Cancer; 2000 Sep; 89(5):995-1003. PubMed ID: 10964329
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic significance of p53, HER-2/neu, Ki-67 and VEGF expression in chondrosarcomas].
Stepanova EV; Kharatishvili TK; Lichinitser MR; Baryshnikov AIu; Solov'ev IuN; Trapeznikov NN
Arkh Patol; 2002; 64(6):9-12. PubMed ID: 12534219
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of parathyroid hormone-related protein (PTHrP) and PTH/PTHrP receptor in cartilaginous tumours: a marker for malignancy?
Kunisada T; Moseley JM; Slavin JL; Martin TJ; Choong PF
Pathology; 2002 Apr; 34(2):133-7. PubMed ID: 12009094
[TBL] [Abstract][Full Text] [Related]
18. Gadd45β expression in chondrosarcoma: a pilot study for diagnostic and biological implications in histological grading.
Zenmyo M; Tanimoto A; Sakakima H; Yokouchi M; Nagano S; Yamamoto T; Ishido Y; Komiya S; Ijiri K
Diagn Pathol; 2010 Oct; 5():69. PubMed ID: 20942912
[TBL] [Abstract][Full Text] [Related]
19. Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma.
Berend KR; Toth AP; Harrelson JM; Layfield LJ; Hey LA; Scully SP
J Bone Joint Surg Am; 1998 Jan; 80(1):11-7. PubMed ID: 9469303
[TBL] [Abstract][Full Text] [Related]
20. Secondary chondrosarcoma in cartilage bone tumors: report of 32 patients.
Altay M; Bayrakci K; Yildiz Y; Erekul S; Saglik Y
J Orthop Sci; 2007 Sep; 12(5):415-23. PubMed ID: 17909925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
